Eisai.Co.Ltd and Biogen has announced that lecanemabs is an investigational anti-amyloid protofibril antibody for treatment of AD(Alzheimer’s Disease) and the US FDA has granted Fast Track designation for it.
Earlier FDA had granted Breakthrough Therapy designation for lecanemabs in June,2021. The Breakthrough Therapy and Fast Track designation are two programs of FDA that are intended to expedite and facilitate new drugs to address unmet medical need for the treatment of serious life threatening conditions.
Morulaa is in the field of Medical Device Consultancy helps medical manufacturers with innovative products enter the Indian Market. In Medical Device Consultancy – we assist in all aspects of commercialization in India with registration being the first step. Contact Morulaa for Medical Device Consultancy which helps medical manufacturers with innovative products enter the Indian Market. In Medical Device Consultancy – we assist in all aspects of commercialization in India with registration being the first step. Contact Morulaa for Medical Device Consultancy in India and South East Asia.
